Capital Institute of Pediatrics, China   Report issue

Academic/Hospital Phase 2 Phase 4
Founded: Beijing China (1958)

Organization Overview

First Clinical Trial
2014
NCT02658500
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2018

Timeline

NOW
  • Now

Alternative names

Capital Institute of Pediatrics, China

Active Ingredients

Drugs in Phase 4 Trials (1)

heparin (liquaemin) (1 trial)

Drugs in Phase 2 Trials (2)

dexamethasone (1 trial)

ruxolitinib (jakafi) (1 trial)

Drugs in Other Trials (2)

human milk (1 trial)

methylprednisolone (medrol) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Lymphohistiocytosis, Hemophagocytic (Phase 2)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 4
  • # of Trial APIs: 5